Tuesday, January 25, 2022
Home Tags HAPB

Tag: HAPB

Telehealth

With Hapbee (HAPBF) Who Needs, Drugs, Caffeine or Nicotine?

Editor / Curator -
Internet Stock Review, Yona Shtern
Client

Hapbee (HAPBF) Selects Accomplished Technology and Consumer Products Entrepreneur & Executive...

Editor / Curator -
Internet Stock Review
2021 Watch List

Stocks On The Move!

Editor / Curator -
hapbee
2021 Watch List

Adding Hapbee Tech (HAPB, HAPBF) $0.34 to Biotech Six Pack Watch...

Editor / Curator -
Hapbee
Health $ Fitness

Popular Wellness Wearable Band, Hapbee (HAPB), Launches New Signal “Bedtime.”

Editor / Curator -
Hapbee
Telehealth

2021 Breakthrough Wearable Tech: Overview on Hapbee (HAPB, HAPBF) and its...

Editor / Curator -
Hapbee
Telehealth

Interview: Scott Donnell from Hapbee (HAPB, HAPBF) on Wall Street Reporter.

Editor / Curator -
Emulate Therapeutics
All News

EMulate Therapeutics to Participate in the Venture Summit – Virtual Connect...

Editor / Curator -
Satori Capital. Hapbee
Telehealth

Investment Manager With $1 Billion in Assets Under Management, Buys 300...

Editor / Curator -
Hapbee, EMulate, HAPB
Telehealth

A Medical Technology That Has The Highest Potential Over Any ...

Editor / Curator -
123Page 1 of 3

Latest article

Revive therapeutics

Our Best Risk to Reward Idea Ever?

2022 Watch List Editor / Curator -
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 pack, 12 Biotech Stocks We Expect to...
Immunix Bio

ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.

2022 Watch List Editor / Curator -
Demonstrates 100% Completion of Planned Treatment Cycles. Immix Biopharma, Inc. Wed, January 19, 2022. ImmixBio...
Fuqua Professor David Ridley

Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.

Biotech News Editor / Curator -
Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.